Imunon, Inc. (NASDAQ:IMNN – Get Rating) fell 1.8% during mid-day trading on Friday . The stock traded as low as $1.29 and last traded at $1.35. 43,140 shares traded hands during trading, a decline of 64% from the average session volume of 119,455 shares. The stock had previously closed at $1.38.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on IMNN shares. Brookline Capital Management reiterated a "buy" rating on shares of Imunon in a report on Monday, November 14th. Alliance Global Partners initiated coverage on shares of Imunon in a research report on Thursday, October 13th. They issued a "buy" rating and a $15.00 target price for the company.

Imunon Price Performance

The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.75 and a current ratio of 4.75. The company's 50-day moving average is $1.44.

Imunon Company Profile

(Get Rating)

Imunon, Inc, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.

Recommended Stories

• Get a free copy of the StockNews.com research report on Imunon (IMNN)
• MarketBeat: Week in Review 12/26 – 12/30
• The Dogs Of Tech: It's Time For A Bite Of These Stocks
• Does This Acquisition Make Microsoft a Bear Market Buy?
• Should You Warm up to Generac Stock for the Winter?
• Is Kintara Therapeutics A Hidden Gem?

Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.